Comparison between MRC Infracon IPO and Q-Line Biotec IPO.
MRC Infracon IPO is a SME Bookbuilding IPO proposed to list at BSE SME while Q-Line Biotec IPO is a SME Bookbuilding proposed to list at NSE SME.
The total issue size of MRC Infracon IPO is up to ₹0.00 Cr whereas the issue size of the Q-Line Biotec IPO is up to ₹0.00 Cr. The final issue price of MRC Infracon IPO is and of Q-Line Biotec IPO is .
| MRC Infracon IPO | Q-Line Biotec IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ||
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 45,00,000 shares | 70,53,200 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 10,00,000 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 55,00,000 shares | 70,53,200 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
MRC Infracon IPO opens on , while Q-Line Biotec IPO opens on . The closing date of MRC Infracon IPO and Q-Line Biotec IPO is , and , respectively.
MRC Infracon IPO P/E ratio is , as compared to Q-Line Biotec IPO P/E ratio of .
| MRC Infracon IPO | Q-Line Biotec IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)MRC Infracon Ltd.'s revenue increased by 33% and profit after tax (PAT) rose by 185% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)Q-Line Biotech Ltd.'s revenue increased by 56% and profit after tax (PAT) dropped by 18% between the financial year ending with March 31, 2025 and March 31, 2024.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 100 | 96.77 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 102.11 | 17.66 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 45.22 | 23.74 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.19 | 0.87 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 102.11 | 23.74 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the MRC Infracon IPO Retail Individual Investors (RII) are offered 0 shares while in Q-Line Biotec IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in MRC Infracon IPO and 0 shares in Q-Line Biotec IPO.
| MRC Infracon IPO | Q-Line Biotec IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 0 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 0 shares | 0 shares |
| NII | 0 shares | 0 shares |
| RII | 0 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 0 shares | 0 shares |
MRC Infracon IPO subscribed in total, whereas Q-Line Biotec IPO subscribed .
